Jupiter Wellness Inc. (JUPW) shares dropped -9.46% at $4.02 at the last check during the premarket session today. During the weekend trading session, Jupiter Wellness stock gained 12.98% to $4.44 per share. JUPW stock recorded an average of 0.98 million shares traded on the day, above the average volume over the past 50 days of 0.14 million shares.
During the last five days, JUPW shares decreased by -0.67%, and over the past month, they declined by -3.27%. Over the past three months, JUPW’s stock price has fallen by -11.02%. As a result of entering into an exclusive licensing agreement, JUPW stock gained ground in the past session but is losing it today.
In what product did JUPW obtain a license?
In addition to developing skin care products, Jupiter Wellness also offers skincare treatments. JUPW’s product pipeline includes the endocannabinoid system as part of its enhanced skin care therapeutics, which target eczema, burns, herpes cold sores, and skin cancer indications. JUPW generates revenue from a growing line of privately-held skincare and wellness products, including CaniSun sunscreen. JUPW’s CBDCaring.com website sells other wellness brands.
In an exclusive license agreement announced on Friday, Jupiter Wellness is licensed to market Photocil, a novel topical cream that combats Psoriasis, Vitiligo and Atopic Dermatitis.
- A license agreement signed between JUPW and Applied Biology (“AB”) makes JUPW the exclusive licensee for Photocil in the U.S.
- In the Agreement, JUPW has access to the copyrights, patents, technology, know-how, trademarks, trade secrets, trademark applications, and trade names of AB related to the use of Photocil by JUPW.
- The rights granted to JUPW to use the intellectual property exclusively entitle the company to manufacture, market, advertise, promote and distribute Photocil for the treatment of skin conditions, including psoriasis and vitiligo.
- In Europe, Asia, and Middle East, Photocil is already available under the names Presilux and MediSun.
- JUPW is expanding and complementing its strategy for treating skin diseases such as Eczema, Psoriasis and Vitiligo through the licensing of Photocil.
- An atopic dermatitis clinical trial involving JW-100, JUPW’s novel topical formulation containing CBD and Aspartame, showed significant reduction in ISGA scores after two weeks in 50% of patients.
- When skin is exposed to direct sunlight, Photocil cream serves as a barrier against non-therapeutic radiation.
- As a result of Photocil cream’s barrier, daytime self-treatment from the sun’s therapeutic (beneficial) UV radiation, commonly referred to as phototherapy, can be achieved safely and effectively.
- Photocil cream replaced the UV photo lamp, which was utilized for phototherapy prior to the advent of Photocil cream.
Jupiter Wellness’ plan for Photocil:
Licenses for Photocil will allow Jupiter Wellness (JUPW) to offer additional treatment options to patients suffering from skin ailments or seeking AM/PM or combination therapies. Upon registration and FDA approval, JUPW plans to market Photocil immediately.
